GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said today that GSK filed a regulatory submission with the FDA for the once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) for patients with chronic obstructive pulmonary disease.
The triple-combo therapy includes 3 drugs: fluticasone furoate, an inhaled corticosteroid; umeclidinium, a long-acting muscarinic antagonist; vilanterol, a long-acting beta2-adrenergic agonist. The medicines are delivered once-daily using GSK’s Ellipta dry powder inhaler.
Get the full story at our sister site, Drug Delivery Business News
The post GSK files for FDA approval of inhaled triple-combo therapy for COPD appeared first on MassDevice.
from MassDevice http://ift.tt/2gCJFDa
Cap comentari:
Publica un comentari a l'entrada